SPOTLIGHT: Genentech licenses Exelixis therapy

Genentech and Exelixis have agreed to a global development pact for XL-518, an MEK-inhibitor for tumors. Exelixis stands to gain up to $40 million in milestones and an upfront fee. Exelixis is responsible for Phase I development. Release

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.